| |
Lux Biosciences to
Present at Jefferies 2nd Annual Healthcare Conference
Jefferies 2nd Annual Healthcare Conference
JERSEY CITY, N.J.--(June 18th, 2008)-- Lux Biosciences, Inc., a
privately held biotechnology company specialized in the field of ophthalmic
diseases, announced today that Ulrich Grau, President and CEO, will present
a company overview at the Jefferies 2nd Annual Healthcare Conference on
Wednesday, June 25th, 2008, at 11:45 AM ET in New York City.
The presentation will be webcast live and may be accessed at
http://www.wsw.com/webcast/jeff26/lux. An archived version of the
webcast will be available at the same location for 30 days following the
presentation.
About Lux
Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused on
ophthalmic diseases. The company has a staged product portfolio of
potentially first-in-class therapies distinguished by their short-term path
to commercialization and potential to generate high revenue growth. The
portfolio includes:
-
Two Phase 3 clinical-stage projects including: i) LX211, the oral
formulation of a next-generation calcineurin inhibitor (voclosporin)
developed as steroid-sparing therapy for the treatment of non-infectious
uveitis, and ii) LX201, a silicone matrix ocular (episcleral) implant
that steadily releases therapeutic doses of cyclosporine A locally to
the eye for the prevention of rejection in cornea transplant recipients.
Both the LUMINATE pivotal clinical program for LX211 for the treatment
of uveitis, as well as the LUCIDA pivotal clinical program with LX201
for the prevention of corneal transplant rejection were initiated in
early 2007 and include sites in North America, Europe and India.
-
LX214, a novel topical eye drop formulation currently in IND-enabling
studies with a target date for entry into the clinic in 2008. LX214 is
based on Lux’ proprietary next-generation calcineurin inhibitor and is
targeted towards other chronic inflammatory diseases of the eye, most
notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.
-
Several earlier stage projects based on proprietary product-enabling
bio-erodible polymer technologies that facilitate targeted and sustained
delivery of molecules to the eye.
For more information on Lux Biosciences, please visit the company’s website
at
www.luxbio.com.
CONTACTS:
Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com
Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net
|
